Aging and Frailty Study

Aging Biomarkers, Geriatric Assessment and Electronic Frailty Index (AGE)

The purpose of this research study is to compare methods to help personalize the prediction of chemotherapy side effects for older adults and to evaluate whether chemotherapy causes changes in the body that are associated with aging.

Primary Objective: Describe mean and variation of the electronic frailty index-cancer, geriatric measures, patient reported outcomes, and biomarkers of aging of chemotherapy, and their change.

Inclusion Criteria:

• Age 65 years and older
• Planned to initiate a new chemotherapy regimen
• Solid tumor malignancy of any stage or lymphoma
• Any performance status
• Ability to understand and the willingness to sign an IRB-approved informed consent document (either directly or via a legally authorized representative).
• Life expectancy of ≥3 months

Exclusion Criteria:

• Initiating biologic, endocrine or immunotherapy only.
• Hematologic malignancy other than lymphoma.
• Concurrent radiation therapy.
• Planned inpatient chemotherapy.